Remdesivir and tixagevimab plus cilgavimab for treating COVID-19

Remdesivir (Veklury, Gilead Sciences) is 'indicated for the treatment of coronavirus disease 2019 (COVID‑19) in:

• adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)

• adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19'.

Tixagevimab plus cilgavimab (Evusheld, AstraZeneca) is indicated 'for the treatment of COVID‑19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19'.

The dosage schedule for remdesivir is available in the summary of product characteristics for remdesivir.

The dosage schedule for tixagevimab plus cilgavimab is available in the summary of product characteristics for tixagevimab plus cilgavimab.

The list price for remdesivir is £340 per 100‑mg vial (excluding VAT; BNF online, accessed October 2022). Costs may vary in different settings because of negotiated procurement discounts.

The company has a commercial arrangement. This makes remdesivir available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

The list price of tixagevimab plus cilgavimab is £800 per 300‑mg dose and £1,600 per 600‑mg dose (excluding VAT; prices provided by company). The company has a commercial arrangement, which would have applied if tixagevimab plus cilgavimab had been recommended.